Highly Sensitive Quenched Fluorescent Substrate of Legionella

Total Page:16

File Type:pdf, Size:1020Kb

Highly Sensitive Quenched Fluorescent Substrate of Legionella Supplemental Material can be found at: http://www.jbc.org/content/suppl/2012/04/23/M111.334334.DC1.html THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 287, NO. 24, pp. 20221–20230, June 8, 2012 © 2012 by The American Society for Biochemistry and Molecular Biology, Inc. Published in the U.S.A. Highly Sensitive Quenched Fluorescent Substrate of Legionella Major Secretory Protein (Msp) Based on Its Structural Analysis*□S Received for publication, December 22, 2011, and in revised form, April 12, 2012 Published, JBC Papers in Press, April 23, 2012, DOI 10.1074/jbc.M111.334334 Hervé Poras‡1, Sophie Duquesnoy‡, Emilie Dange‡, Anthony Pinon§, Michèle Vialette§, Marie-Claude Fournié-Zaluski‡, and Tanja Ouimet‡ From ‡Pharmaleads, Paris BioPark, 11 Rue Watt 75013 Paris and the §Institut Pasteur Lille, Unité de Sécurité Microbiologique, 1 Rue du Professeur Calmette, 59019 Lille Cedex, France Background: Legionella pneumophila secretes a protease without known specific substrate and three-dimensional structure. Results: Analysis of a quenched peptide library identified a lead substrate, ameliorated by rational design, using an Msp structural model obtained by the x-ray structure of pseudolysin. Conclusion: The study identifies the first selective substrate for Msp. Significance: This substrate could be useful for Legionella detection. Downloaded from Legionella pneumophila has been shown to secrete a protease (phosphatase, phospholipase C, proteases, and kinases), and termed major secretory protein (Msp). This protease belongs to the Mip gene product (1). the M4 family of metalloproteases and shares 62.9% sequence Among the proteases, one exotoxin, abundantly secreted by similarity with pseudolysin (EC 3.4.24.26). With the aim of different strains of L. pneumophila, was detected (2) and shown www.jbc.org developing a specific enzymatic assay for the detection and to possess a proteolytic activity toward some human serum quantification of Msp, the Fluofast substrate library was proteins (3), collagen, casein, gelatin, and hide powder but not screened using both enzymes in parallel. Moreover, based on the elastin (4). This extracellular protease, designated as major 2 crystal structure of pseudolysin, a model of the Msp structure secretory protein (Msp), has been purified from L. pneumo- at INSERM, on October 11, 2012 was built. Screening of the peptide library identified a lead sub- phila culture filtrates (5) and characterized as a neutral zinc- strate specifically cleaved by Msp that was subsequently opti- containing metalloprotease of 38 kDa, exhibiting hemolytic and mized by rational design. The proposed model for Msp is con- cytotoxic activities (6). sistent with the enzymatic characteristics of the studied peptide The protease has been cloned (7), and analysis of the gene has substrates and provides new structural information useful for shown that it encodes a large preproenzyme of 543 amino acids the characterization of the protease. This study leads to the (60,775 Da) transported to the periplasma before maturation identification of the first selective and high affinity substrate for into the 38-kDa active protein. The protease belongs to the M4 Msp that is able to detect picomolar concentrations of the puri- family of metalloproteases (clan MA/E) represented by its fied enzyme. The identified substrate could be useful for the archetypal member thermolysin. Within the M4 family, Msp development of a novel method for the rapid detection of shares the highest structural and functional homologies with Legionella. pseudolysin (Pseudomonas aeruginosa elastase, EC 3.4.24.26) (8, 9). Comparison of their amino acid sequences allowed the characterization of the main residues involved in the proteo- Legionella is a genus of Gram-negative bacteria, widely dis- lytic activity of Msp, i.e. the consensus sequences 377HEVSH381 tributed in freshwater environments, where it survives as intra- and 401ESFSD405 containing the three zinc ligands His377, cellular parasites of protozoa. Among the different species of His381, Glu401, and the catalytic glutamate Glu378. As expected, Legionella, the most frequently associated with human disease the mutation of E378Q leads to an inactive protease deprived of is Legionella pneumophila, causing acute pneumonia, referred cytotoxic activity (9), thus probing the involvement of the to as legionellosis, and Pontiac fever, a severe influenza-like hydrolytic properties of the protease in L. pneumophila illness. In the human lung, the bacteria are able to replicate pathogenesis. within alveolar macrophages and epithelial cells, causing tissue A chromogenic substrate MeO-succinimide-Arg-Pro-Tyr- damage. Several potential virulence factors have been identified p-nitroanilide (S-2586), initially developed for ␣-chymotrypsin in L. pneumophila, including a peptide toxin, various enzymes (10), has been used to detect Msp in different strains of Legio- nella (11, 12). Despite the lack of specificity of this substrate, species-discriminating responses were obtained. All the sero- * This work was supported by a grant from Agence Nationale pour la Recher- che (Programme de Recherche sur les ECOtechnologies et le Développe- ment Durable, Ralf project). 2 The abbreviations used are: Msp, major secretory protein; HPI, N-(1-carboxy- □ S This article contains supplemental Fig. 1. 3-phenylpropyl)-phenylalanyl-␣-asparagine; Nop, (p-nitro)-L-phenylala- 1 To whom correspondence should be addressed. Tel.: 33144066095; Fax: nine; Pya, L-pyrenylalanine; Fmoc, N-(9-fluorenyl)methoxycarbonyl; Orn, 33144066099; E-mail: [email protected]. ornithine; hSer, homo-serine; hArg, homo-arginine. JUNE 8, 2012•VOLUME 287•NUMBER 24 JOURNAL OF BIOLOGICAL CHEMISTRY 20221 Fluorescently Quenched Substrate of Legionella Endopeptidase groups of L. pneumophila cleaved this substrate, whereas other continuous shaking. The final volume of each culture was 3 Legionella species (2 of 5), Pseudomonas strains (4 of 8), or liters. A sample was removed for enumeration on BCYE␣, and Enterobacteriaceae strains (0 of 11) were cleaved poorly or were the remaining culture medium was centrifuged at 5000 rpm for not responsive. These results suggested a relatively high speci- 10 min at 20 °C to remove suspended matter. The supernatant ficity of L. pneumophila Msp as compared with analogous was filter-sterilized on a 0.2-␮m membrane (Millipore). secreted activities of other bacteria. Msp has interesting prop- Purification—Msp was purified based on the protocol from erties, i.e. its abundant secretion, its possible implication in L. Dreyfus and Iglewski (5). Proteins from the sterilized culture pneumophila pathogenicity, and its specificity toward other media were precipitated overnight at 4 °C under constant stir- pathogens. Taking into account these properties, the aim of this ring with 65% ammonium sulfate. The media were then centri- study was to develop a highly sensitive and selective substrate of fuged at 14,000 rpm for 30 min at 4 °C, and the protein pellets Msp as a marker of L. pneumophila. were resuspended using 25 mM Tris-HCl, pH 7.8, 25 mM NaCl, Consequently, based on the crystal structure of pseudolysin, 0.01% Triton X-100 (buffer A), loaded on a HiPrep 26/10 desalt- obtained with 1.5-Å resolution (13), a three-dimensional model ing column (GE Healthcare, Akta Systems), and eluted in the of Msp was constructed and refined. The secreted Msp protease same buffer at a flow rate of 10 ml/min. The fractions contain- was purified from culture media of L. pneumophila Philadel- ing Msp activity (identified by SDS-PAGE or enzymatic activ- phia 1 (CIP 103854T-ATCC 33152). The Fluofast library of ity) were pooled (120 ml) and concentrated (ϳ10 ml at 4 °C intramolecularly quenched fluorescent substrates containing using Amicon Ultra-15 (cutoff of 10 kDa) (Millipore)). The con- the Pya/Nop fluorophore/quencher pair (14, 15) was screened centrated fraction was loaded onto a HiPrep DEAE FF 16/10 in parallel with purified Msp and pseudolysin. Results of this column (GE Healthcare, Akta Systems) equilibrated with buffer Downloaded from screening provided a lead selective substrate. Docking of this A, and the protein was eluted according to a multistep gradient substrate in the three-dimensional model of Msp and sequence buffer B (25 mM Tris-HCl, pH 7.8, 1 M NaCl, 0.01% Triton refinement based on the observed substrate-enzyme interac- X-100). The first step consisted of 15% of buffer B (6 column tions allowed the synthesis of highly efficient and selective sub- volumes), the second of 60% of buffer B (6 column volumes), strates of L. pneumophila Msp. and the last elution step was set at 100% of the same (5 column volumes). The fractions containing Msp activity, eluting at 60% www.jbc.org EXPERIMENTAL PROCEDURES buffer B, were pooled and concentrated to a volume of 200 ␮lat Reagents—Fmoc-protected amino acids, piperidine, N-methyl- 4 °C. This concentrated fraction was loaded onto a HiLoad pyrrolidone, dichloromethane, dicyclohexylcarbodiimide, 16/60 Superdex 75 preparation grade (GE Healthcare, Akta at INSERM, on October 11, 2012 1-hydroxybenzotriazole, and O-(7-azabenzotriazol-1-yl)- Systems) and eluted in 500-␮l fractions with 25 mM Tris-HCl, 1,1,3,3-tetramethyluronium were purchased from Applied pH 7.2, 0.15 M NaCl, 0.01% Triton X-100 at a flow rate of 0.25 Biosystems (Courtaboeuf, France). Fmoc-(p-Nitro)-L-phenyl- ml/min across 1.5 bed volumes. The pure fractions containing alanine and methylbenzhydrylamine resin (0.73 mmol/g) were Msp activity were pooled and concentrated using Amicon Ultra from Novabiochem. Fmoc-L-pyrenylalanine (Pya), prepared as 10-kDa ultrafiltration. Proteins were quantified using BCA described previously (16), were from Polypeptide Laboratories (Pierce). (Strasbourg, France). Trifluoroacetic acid was from SDS-Carlo The purified preparation was electrophoresed on a 12% Erba (France). Triisopropylsilane was from Sigma. BCYE␣ acrylamide denaturing gel, silver-stained, and quantified by (agar-solidified Buffered Charcoal Yeast Extract supplemented densitometry using a BSA scale and the Quantity One program with 0.1% ␣-ketoglutarate) was obtained from Oxoid (Basing- of Bio-Rad. Purity of the preparation was also evaluated using stoke, UK).
Recommended publications
  • Proteases, Mucus, and Mucosal Immunity in Chronic Lung Disease
    International Journal of Molecular Sciences Review Proteases, Mucus, and Mucosal Immunity in Chronic Lung Disease Michael C. McKelvey 1 , Ryan Brown 1, Sinéad Ryan 1, Marcus A. Mall 2,3,4 , Sinéad Weldon 1 and Clifford C. Taggart 1,* 1 Airway Innate Immunity Research (AiiR) Group, Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University Belfast, Belfast BT9 7BL, UK; [email protected] (M.C.M.); [email protected] (R.B.); [email protected] (S.R.); [email protected] (S.W.) 2 Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité—Universitätsmedizin Berlin, 13353 Berlin, Germany; [email protected] 3 Berlin Institute of Health (BIH), 10178 Berlin, Germany 4 German Center for Lung Research (DZL), 35392 Gießen, Germany * Correspondence: [email protected]; Tel.: +44-289097-6383 Abstract: Dysregulated protease activity has long been implicated in the pathogenesis of chronic lung diseases and especially in conditions that display mucus obstruction, such as chronic obstructive pulmonary disease, cystic fibrosis, and non-cystic fibrosis bronchiectasis. However, our appreciation of the roles of proteases in various aspects of such diseases continues to grow. Patients with muco- obstructive lung disease experience progressive spirals of inflammation, mucostasis, airway infection and lung function decline. Some therapies exist for the treatment of these symptoms, but they are unable to halt disease progression and patients may benefit from novel adjunct therapies. In this review, we highlight how proteases act as multifunctional enzymes that are vital for normal Citation: McKelvey, M.C.; Brown, R.; airway homeostasis but, when their activity becomes immoderate, also directly contribute to airway Ryan, S.; Mall, M.A.; Weldon, S.; dysfunction, and impair the processes that could resolve disease.
    [Show full text]
  • Serine Proteases with Altered Sensitivity to Activity-Modulating
    (19) & (11) EP 2 045 321 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.04.2009 Bulletin 2009/15 C12N 9/00 (2006.01) C12N 15/00 (2006.01) C12Q 1/37 (2006.01) (21) Application number: 09150549.5 (22) Date of filing: 26.05.2006 (84) Designated Contracting States: • Haupts, Ulrich AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 51519 Odenthal (DE) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Coco, Wayne SK TR 50737 Köln (DE) •Tebbe, Jan (30) Priority: 27.05.2005 EP 05104543 50733 Köln (DE) • Votsmeier, Christian (62) Document number(s) of the earlier application(s) in 50259 Pulheim (DE) accordance with Art. 76 EPC: • Scheidig, Andreas 06763303.2 / 1 883 696 50823 Köln (DE) (71) Applicant: Direvo Biotech AG (74) Representative: von Kreisler Selting Werner 50829 Köln (DE) Patentanwälte P.O. Box 10 22 41 (72) Inventors: 50462 Köln (DE) • Koltermann, André 82057 Icking (DE) Remarks: • Kettling, Ulrich This application was filed on 14-01-2009 as a 81477 München (DE) divisional application to the application mentioned under INID code 62. (54) Serine proteases with altered sensitivity to activity-modulating substances (57) The present invention provides variants of ser- screening of the library in the presence of one or several ine proteases of the S1 class with altered sensitivity to activity-modulating substances, selection of variants with one or more activity-modulating substances. A method altered sensitivity to one or several activity-modulating for the generation of such proteases is disclosed, com- substances and isolation of those polynucleotide se- prising the provision of a protease library encoding poly- quences that encode for the selected variants.
    [Show full text]
  • Activation of Human Pro-Urokinase by Unrelated Proteases Secreted By
    Activation of human pro-urokinase by unrelated proteases secreted by Pseudomonas aeruginosa Nathalie Beaufort, Paulina Seweryn, Sophie de Bentzmann, Aihua Tang, Josef Kellermann, Nicolai Grebenchtchikov, Manfred Schmitt, Christian Sommerhoff, Dominique Pidard, Viktor Magdolen To cite this version: Nathalie Beaufort, Paulina Seweryn, Sophie de Bentzmann, Aihua Tang, Josef Kellermann, et al.. Activation of human pro-urokinase by unrelated proteases secreted by Pseudomonas aeruginosa: LasB and protease IV activate human pro-urokinase. Biochemical Journal, Portland Press, 2010, 428 (3), pp.473-482. 10.1042/BJ20091806. hal-00486859 HAL Id: hal-00486859 https://hal.archives-ouvertes.fr/hal-00486859 Submitted on 27 May 2010 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Biochemical Journal Immediate Publication. Published on 25 Mar 2010 as manuscript BJ20091806 ACTIVATION OF HUMAN PRO-UROKINASE BY UNRELATED PROTEASES SECRETED BY PSEUDOMONAS AERUGINOSA Nathalie Beaufort*,†,1, Paulina Seweryn*, Sophie de Bentzmann‡, Aihua Tang§, Josef Kellermannll, Nicolai
    [Show full text]
  • Recent Advances in Surface Nanoengineering for Biofilm
    nanomaterials Review Recent Advances in Surface Nanoengineering for Biofilm Prevention and Control. Part II: Active, Combined Active and Passive, and Smart Bacteria-Responsive Antibiofilm Nanocoatings 1, 2, , Paul Cătălin Balaure y and Alexandru Mihai Grumezescu * y 1 “Costin Nenitzescu” Department of Organic Chemistry, Faculty of Applied Chemistry and Materials Science, University Politehnica of Bucharest, G. Polizu Street 1–7, 011061 Bucharest, Romania; [email protected] 2 Department of Science and Engineering of Oxide Materials and Nanomaterials, Faculty of Applied Chemistry and Materials Science, University Politehnica of Bucharest, G. Polizu Street 1–7, 011061 Bucharest, Romania * Correspondence: [email protected]; Tel.: +40-21-402-39-97 These authors contributed equally to this work. y Received: 28 June 2020; Accepted: 28 July 2020; Published: 4 August 2020 Abstract: The second part of our review describing new achievements in the field of biofilm prevention and control, begins with a discussion of the active antibiofilm nanocoatings. We present the antibiofilm strategies based on antimicrobial agents that kill pathogens, inhibit their growth, or disrupt the molecular mechanisms of biofilm-associated increase in resistance and tolerance. These agents of various chemical structures act through a plethora of mechanisms targeting vital bacterial metabolic pathways or cellular structures like cell walls and cell membranes or interfering with the processes that underlie different stages of the biofilm life cycle. We illustrate the latter
    [Show full text]
  • Identification of Pseudolysin (Lasb)
    nature publishing group ORIGINAL CONTRIBUTIONS 1 see related editorial on page x Identifi cation of Pseudolysin (lasB) as an Aciduric Gluten-Degrading Enzyme with High Therapeutic Potential for Celiac Disease Guoxian Wei , DDS, MS, PhD 1 , Na Tian , DDS, MS, PhD 1 , Adriana C. Valery , DDS1 , Yi Zhong , DDS 1 , Detlef Schuppan , MD, PhD 2 , 3 and Eva J. Helmerhorst , MS, PhD1 OBJECTIVES: Immunogenic gluten proteins implicated in celiac disease (CD) largely resist degradation by human digestive enzymes. Here we pursued the isolation of gluten-degrading organisms from human feces, aiming at bacteria that would digest gluten under acidic conditions, as prevails in the stomach. COLON/SMALL BOWEL METHODS: Bacteria with gluten-degrading activities were isolated using selective gluten agar plates at pH 4.0 and 7.0. Proteins in concentrated bacterial cell sonicates were separated by diethylaminoethanol chromatography. Enzyme activity was monitored with chromogenic substrates and gliadin zymography. Elimination of major immunogenic gluten epitopes was studied with R5 and G12 enzyme-linked immunosorbent assays. RESULTS: Gliadin-degrading enzyme activities were observed for 43 fecal isolates, displaying activities in the ~150–200 and <50 kDa regions. The active strains were identifi ed as Pseudomonas aeruginosa . Gliadin degradation in gel was observed from pH 2.0 to 7.0. Liquid chromatography–electrospray ionization–tandem mass spectrometry analysis identifi ed the enzyme as pseudolysin (lasB), a metalloprotease belonging to the thermolysin (M4) family proteases. Its electrophoretic mobility in SDS–polyacrylamide gel electrophoresis and gliadin zymogram gels was similar to that of a commercial lasB preparation, with tendency of oligomerization. Pseudolysin eliminated epitopes recognized by the R5 antibody, while those detected by the G12 antibody remained intact, despite destruction of the nearby major T-cell epitope QPQLPY.
    [Show full text]
  • Anticoagulant Property of Metalloprotease Produced by Pseudomonas Fluorescens Migula B426
    Research Article Annals of Genetics and Genetic Disorders Published: 27 Sep, 2018 Anticoagulant Property of Metalloprotease Produced by Pseudomonas fluorescens Migula B426 Usharani Brammacharry1 and Muthuraj Muthaiah2* 1Department of Biomedical Genetics, University of Madras, India 2State TB Training and Demonstration Centre, Intermediate Reference Laboratory, India Abstract In this study we endeavoured for the production, purification and characterization of anticoagulant property of metalloprotease enzyme from Pseudomonas fluorescens Migula B426 strain. Shake flask fermentation was performed to produce the enzyme and the fibrinolytic activities of the enzyme of this isolate. These were estimated to range across 40 to 5000 IU/mL of urokinase through the standard curve using the thrombolytic area on the fibrin plate. Purification of crude enzyme was done through Sephadex S-300 gel filtration and its activity was 2474 IU/mL.Enzyme activity was enhanced bydivalent cations Mg2+ and Ca2+ in the presence of Ethylene Diamine Tetra Acetic acid (EDTA), a metal-chelating agent and two metalloprotease inhibitors, 2, 2′-bipyridine and o-phenanthroline, repressed the enzymatic activity significantly. Amino acids of N-terminal sequence have great similarity with those of metalloprotease from various Pseudomonas strains and have consensus sequence, HEXXH zinc binding motif. These results strongly suggest that the extracellular protease enzyme of P.fluorescens Migula B426 strain is a novel zinc metalloprotease and is based on its N-terminal amino acid sequence, effect of protease inhibitors and its fibrinolytic activity. It can be further developed as a potential candidate for thrombolytic therapy. Keywords: Fibrin; Metalloprotease; Pseudomonas fluorescens; Zinc binding motif Introduction OPEN ACCESS Extracellular proteases have great commercial value and find multiple applications in various *Correspondence: industrial sectors.
    [Show full text]
  • Handbook of Proteolytic Enzymes Second Edition Volume 1 Aspartic and Metallo Peptidases
    Handbook of Proteolytic Enzymes Second Edition Volume 1 Aspartic and Metallo Peptidases Alan J. Barrett Neil D. Rawlings J. Fred Woessner Editor biographies xxi Contributors xxiii Preface xxxi Introduction ' Abbreviations xxxvii ASPARTIC PEPTIDASES Introduction 1 Aspartic peptidases and their clans 3 2 Catalytic pathway of aspartic peptidases 12 Clan AA Family Al 3 Pepsin A 19 4 Pepsin B 28 5 Chymosin 29 6 Cathepsin E 33 7 Gastricsin 38 8 Cathepsin D 43 9 Napsin A 52 10 Renin 54 11 Mouse submandibular renin 62 12 Memapsin 1 64 13 Memapsin 2 66 14 Plasmepsins 70 15 Plasmepsin II 73 16 Tick heme-binding aspartic proteinase 76 17 Phytepsin 77 18 Nepenthesin 85 19 Saccharopepsin 87 20 Neurosporapepsin 90 21 Acrocylindropepsin 9 1 22 Aspergillopepsin I 92 23 Penicillopepsin 99 24 Endothiapepsin 104 25 Rhizopuspepsin 108 26 Mucorpepsin 11 1 27 Polyporopepsin 113 28 Candidapepsin 115 29 Candiparapsin 120 30 Canditropsin 123 31 Syncephapepsin 125 32 Barrierpepsin 126 33 Yapsin 1 128 34 Yapsin 2 132 35 Yapsin A 133 36 Pregnancy-associated glycoproteins 135 37 Pepsin F 137 38 Rhodotorulapepsin 139 39 Cladosporopepsin 140 40 Pycnoporopepsin 141 Family A2 and others 41 Human immunodeficiency virus 1 retropepsin 144 42 Human immunodeficiency virus 2 retropepsin 154 43 Simian immunodeficiency virus retropepsin 158 44 Equine infectious anemia virus retropepsin 160 45 Rous sarcoma virus retropepsin and avian myeloblastosis virus retropepsin 163 46 Human T-cell leukemia virus type I (HTLV-I) retropepsin 166 47 Bovine leukemia virus retropepsin 169 48
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,561,811 B2 Bluchel Et Al
    USOO8561811 B2 (12) United States Patent (10) Patent No.: US 8,561,811 B2 Bluchel et al. (45) Date of Patent: Oct. 22, 2013 (54) SUBSTRATE FOR IMMOBILIZING (56) References Cited FUNCTIONAL SUBSTANCES AND METHOD FOR PREPARING THE SAME U.S. PATENT DOCUMENTS 3,952,053 A 4, 1976 Brown, Jr. et al. (71) Applicants: Christian Gert Bluchel, Singapore 4.415,663 A 1 1/1983 Symon et al. (SG); Yanmei Wang, Singapore (SG) 4,576,928 A 3, 1986 Tani et al. 4.915,839 A 4, 1990 Marinaccio et al. (72) Inventors: Christian Gert Bluchel, Singapore 6,946,527 B2 9, 2005 Lemke et al. (SG); Yanmei Wang, Singapore (SG) FOREIGN PATENT DOCUMENTS (73) Assignee: Temasek Polytechnic, Singapore (SG) CN 101596422 A 12/2009 JP 2253813 A 10, 1990 (*) Notice: Subject to any disclaimer, the term of this JP 2258006 A 10, 1990 patent is extended or adjusted under 35 WO O2O2585 A2 1, 2002 U.S.C. 154(b) by 0 days. OTHER PUBLICATIONS (21) Appl. No.: 13/837,254 Inaternational Search Report for PCT/SG2011/000069 mailing date (22) Filed: Mar 15, 2013 of Apr. 12, 2011. Suen, Shing-Yi, et al. “Comparison of Ligand Density and Protein (65) Prior Publication Data Adsorption on Dye Affinity Membranes Using Difference Spacer Arms'. Separation Science and Technology, 35:1 (2000), pp. 69-87. US 2013/0210111A1 Aug. 15, 2013 Related U.S. Application Data Primary Examiner — Chester Barry (62) Division of application No. 13/580,055, filed as (74) Attorney, Agent, or Firm — Cantor Colburn LLP application No.
    [Show full text]
  • DEN180014 Summary
    EVALUATION OF AUTOMATIC CLASS III DESIGNATION FOR WOUNDCHEK Bacterial Status DECISION SUMMARY A. De Novo Number: DEN180014 B. Purpose for Submission: De Novo request for evaluation of automatic class III designation for the WOUNDCHEK Bacterial Status C. Measurand: Bacterial Proteases D. Type of Test: Lateral flow chromatographic assay E. Applicant: Alere Scarborough, Inc. F. Proprietary and Established Names: WOUNDCHEK Bacterial Status WCBS G. Regulatory Information: 1. Regulation section: 21 CFR 866.3231 2. Classification: Class II 1 3. Product code(s): QFA 4. Panel: Microbiology (83) H. Indications For Use: 1. Indication(s) for use: WOUNDCHEK Bacterial Status (WCBS) is an in vitro diagnostic chromatographic test for the qualitative detection of bacterial protease activity directly from wound fluid samples collected with a swab. The WCBS test is intended for use in adult patients as an aid in assessing the risk for non-healing of chronic venous, diabetic foot, and pressure ulcers associated with wounds where there are no signs of wound infection and where patients are asymptomatic for clinical signs of infection. The test is intended for use with chronic wounds that are between 21 days and < 6 months of age and chronic wounds that are ≥ 6 months of age that are < 1cm2 in size. This test is indicated for use solely by health care professionals whose clinical practice primarily or routinely involves the assessment and treatment of chronic wounds. WCBS results are intended for use in conjunction with the assessment of other known risk factors for wound healing that significantly contribute to the assessment of risk for non- healing chronic wounds such as wound age, wound size, and vascular status.
    [Show full text]
  • Kinetic and Docking Studies of Inhibitors Targeting the Catalytic Zinc in MA Clan Enzymes
    FACULTY OF HEALTH SCIENCE DEPARTMENT OF MEDICAL BIOLOGY TUMOUR BIOLOGY RESEARCH GROUP Kinetic and docking studies of inhibitors targeting the catalytic zinc in MA clan enzymes Stian Sjøli A dissertation for the degree of Philosophiae Doctor October 2011 Table of Contents Acknowledgements…………………………………………………… i List of manuscripts………………………………………………….... iv List of abbreviations………………………………………………….. v Preface………………………………………………………………… vi Aim of Study………………………………………………………….. 1 Introduction …………………………………………………………... 2 1. Enzymes…………………………………………………………... 2 1.1. Kinetics of Catalysis ………………………………………… 3 1.2. Thermodynamics of catalysis ……………………………….. 6 1.3. Breaking peptide bonds with water………………………….. 9 1.4. Binding substrates……………………………………………. 11 1.5. Substrate specificity………………………………………….. 11 1.5.1. Catalytic chamber…………………………………….. 14 1.5.2. Triple helical hydrolysis………………………………. 15 1.6. Families of Metalloprotease………………………………….. 16 1.6.1. Activation mechanism ……………………………….. 17 1.6.2. M4 the Thermolysin family…………………………... 20 Thermolysin………………………………………………. 20 Pseudolysin……………………………………………….. 21 1.6.3. M10A the MMP-1 family…………………………….. 22 Gelatinases ……………………………………………….. 23 MMP-2……………………………………………………. 23 MMP-9……………………………………………………. 24 MMP-14…………………………………………………... 24 1.6.4. M13 the Neprilysin family……………………………. 25 2. Pathological roles for MePs………………………………………. 26 2.1. Tumor metastasis…………………………………………….. 26 2.2. Bacterial invasion and sepsis………………………………… 28 2.3. Extracellular matrix degradation…………………………….. 29 2.4. Blood vessel regulation ………………………………………
    [Show full text]
  • Peptide Sequence
    Peptide Sequence Annotation AADHDG CAS-L1 AAEAISDA M10.005-stromelysin 1 (MMP-3) AAEHDG CAS-L2 AAEYGAEA A01.009-cathepsin D AAGAMFLE M10.007-stromelysin 3 (MMP-11) AAQNASMW A06.001-nodavirus endopeptidase AASGFASP M04.003-vibriolysin ADAHDG CAS-L3 ADAPKGGG M02.006-angiotensin-converting enzyme 2 ADATDG CAS-L5 ADAVMDNP A01.009-cathepsin D ADDPDG CAS-21 ADEPDG CAS-L11 ADETDG CAS-22 ADEVDG CAS-23 ADGKKPSS S01.233-plasmin AEALERMF A01.009-cathepsin D AEEQGVTD C03.007-rhinovirus picornain 3C AETFYVDG A02.001-HIV-1 retropepsin AETWYIDG A02.007-feline immunodeficiency virus retropepsin AFAHDG CAS-L24 AFATDG CAS-25 AFDHDG CAS-L26 AFDTDG CAS-27 AFEHDG CAS-28 AFETDG CAS-29 AFGHDG CAS-30 AFGTDG CAS-31 AFQHDG CAS-32 AFQTDG CAS-33 AFSHDG CAS-L34 AFSTDG CAS-35 AFTHDG CAS-L36 AGERGFFY Insulin B-chain AGLQRGGG M14.004-carboxypeptidase N AGSHLVEA Insulin B-chain AIDIDG CAS-L37 AIDPDG CAS-38 AIDTDG CAS-39 AIDVDG CAS-L40 AIEHDG CAS-L41 AIEIDG CAS-L42 AIENDG CAS-43 AIEPDG CAS-44 AIEQDG CAS-45 AIESDG CAS-46 AIETDG CAS-47 AIEVDG CAS-48 AIFQGPID C03.007-rhinovirus picornain 3C AIGHDG CAS-49 AIGNDG CAS-L50 AIGPDG CAS-L51 AIGQDG CAS-52 AIGSDG CAS-53 AIGTDG CAS-54 AIPMSIPP M10.051-serralysin AISHDG CAS-L55 AISNDG CAS-L56 AISPDG CAS-57 AISQDG CAS-58 AISSDG CAS-59 AISTDG CAS-L60 AKQRAKRD S08.071-furin AKRQGLPV C03.007-rhinovirus picornain 3C AKRRAKRD S08.071-furin AKRRTKRD S08.071-furin ALAALAKK M11.001-gametolysin ALDIDG CAS-L61 ALDPDG CAS-62 ALDTDG CAS-63 ALDVDG CAS-L64 ALEIDG CAS-L65 ALEPDG CAS-L66 ALETDG CAS-67 ALEVDG CAS-68 ALFQGPLQ C03.001-poliovirus-type picornain
    [Show full text]
  • Information to Users
    INFORMATION TO USERS This manuscript has been reproduced from the microfihn master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while others may be from any type of computer printer. The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely event that the author did not send UMI a complete manuscript and there are missing pages, these will be noted. Also, if unauthorized copyright material had to be removed, a note will indicate the deletion. Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning the original, beginning at the upper left-hand comer and continuing from left to right in equal sections with small overlaps. Each original is also photographed in one exposure and is included in reduced form at the back of the book. Photographs included in the original manuscript have been reproduced xerographically in this copy. Higher quality 6” x 9” black and white photographic prints are available for any photographs or illustrations appearing in this copy for an additional charge. Contact UMI directly to order. UMI A Bell & Howell Information Company 300 North Zeeb Road, Ann Arbor MI 48106-1346 USA 313/761-4700 800/521-0600 COMPARATIVE ANALYSIS OF PSEUDOMONAS AERUGINOSA LASA AND LASD DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Sukjoon Park, B.
    [Show full text]